Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 86

1.

Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial.

Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, von Minckwitz G, Chia SKL, Mansi J, Barrios CH, Gnant M, Tomašević Z, Denduluri N, Šeparović R, Gokmen E, Bashford A, Ruiz Borrego M, Kim SB, Jakobsen EH, Ciceniene A, Inoue K, Overkamp F, Heijns JB, Armstrong AC, Link JS, Joy AA, Bryce R, Wong A, Moran S, Yao B, Xu F, Auerbach A, Buyse M, Chan A; ExteNET Study Group.

Lancet Oncol. 2017 Dec;18(12):1688-1700. doi: 10.1016/S1470-2045(17)30717-9. Epub 2017 Nov 13.

PMID:
29146401
2.

Assessment of the Role of Everolimus Therapy in Patients with Renal Cell Carcinoma Based on Daily Routine and Recent Research Results.

Maráz A, Csejtei A, Kocsis J, Szűcs M, Kahán Z, Bodoky G, Dank M, Mangel L, Révész J, Varga Z, Géczi L.

Pathol Oncol Res. 2017 Oct 13. doi: 10.1007/s12253-017-0317-0. [Epub ahead of print]

PMID:
29027615
3.

Comparison of Circulating miRNAs Expression Alterations in Matched Tissue and Plasma Samples During Colorectal Cancer Progression.

Nagy ZB, Barták BK, Kalmár A, Galamb O, Wichmann B, Dank M, Igaz P, Tulassay Z, Molnár B.

Pathol Oncol Res. 2017 Oct 4. doi: 10.1007/s12253-017-0308-1. [Epub ahead of print]

PMID:
28980150
4.

PD-1, PD-L1 and CTLA-4 in pregnancy-related - and in early-onset breast cancer: A comparative study.

Ács B, Madaras L, Tőkés AM, Kovács AK, Kovács E, Ozsvári-Vidákovich M, Karászi Á, Birtalan E, Dank M, Szász AM, Kulka J.

Breast. 2017 Oct;35:69-77. doi: 10.1016/j.breast.2017.06.013. Epub 2017 Jun 23.

PMID:
28651116
5.

Erratum: Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations.

Brown D, Smeets D, Székely B, Larsimont D, Szász AM, Adnet PY, Rothé F, Rouas G, Nagy ZI, Faragó Z, Tőkés AM, Dank M, Szentmártoni G, Udvarhelyi N, Zoppoli G, Pusztai L, Piccart M, Kulka J, Lambrechts D, Sotiriou C, Desmedt C.

Nat Commun. 2017 Jun 6;8:15759. doi: 10.1038/ncomms15759. Erratum in: Nat Commun. 2017 Apr 20;8:14944.

6.

Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations.

Brown D, Smeets D, Székely B, Larsimont D, Szász AM, Adnet PY, Rothé F, Rouas G, Nagy ZI, Faragó Z, Tőkés AM, Dank M, Szentmártoni G, Udvarhelyi N, Zoppoli G, Pusztai L, Piccart M, Kulka J, Lambrechts D, Sotiriou C, Desmedt C.

Nat Commun. 2017 Apr 20;8:14944. doi: 10.1038/ncomms14944. Erratum in: Nat Commun. 2017 Jun 06;8:15759.

7.

A Retrospective Analysis of the First 41 mCRPC Patients with Bone Pain Treated with Radium-223 at the National Institute of Oncology in Hungary.

Küronya Z, Sinkovics I, Ágoston P, Bíró K, Bodrogi I, Böde I, Dank M, Gyergyay F, Vajdics T, Kolonics Z, Nagyiványi K, Rúzsa Á, Géczi L.

Pathol Oncol Res. 2017 Oct;23(4):777-783. doi: 10.1007/s12253-017-0190-x. Epub 2017 Jan 10.

PMID:
28074331
8.

Comparison of immunophenotypes of primary breast carcinomas and multiple corresponding distant metastases: an autopsy study of 25 patients.

Szekely B, Nagy ZI, Farago Z, Kiss O, Lotz G, Kovacs KA, Madaras L, Udvarhelyi N, Dank M, Szentmartoni G, Baranyai Z, Harsanyi L, Tőkés AM, Timar J, Szasz AM, Kulka J.

Clin Exp Metastasis. 2017 Jan;34(1):103-113. doi: 10.1007/s10585-016-9830-x. Epub 2016 Nov 24.

PMID:
27885435
9.

Do Substance Use, Psychosocial Adjustment, and Sexual Experiences Vary for Dating Violence Victims Based on Type of Violent Relationships?

Zweig JM, Yahner J, Dank M, Lachman P.

J Sch Health. 2016 Dec;86(12):882-887. doi: 10.1111/josh.12453.

PMID:
27866389
10.

[Systemic therapy of breast cancer: practice guideline].

Horváth Z, Boér K, Dank M, Kahán Z, Kocsis J, Kövér E, Pajkos G, Pikó B, Rubovszky G, Eckhardt S.

Magy Onkol. 2016 Sep;60(3):241-57. Epub 2016 Jul 14. Hungarian.

11.

Bevacizumab plus paclitaxel versus bevacizumab plus capecitabine as first-line treatment for HER2-negative metastatic breast cancer (TURANDOT): primary endpoint results of a randomised, open-label, non-inferiority, phase 3 trial.

Zielinski C, Láng I, Inbar M, Kahán Z, Greil R, Beslija S, Stemmer SM, Zvirbule Z, Steger GG, Melichar B, Pienkowski T, Sirbu D, Petruzelka L, Eniu A, Nisenbaum B, Dank M, Anghel R, Messinger D, Brodowicz T; TURANDOT investigators.

Lancet Oncol. 2016 Sep;17(9):1230-9. doi: 10.1016/S1470-2045(16)30154-1. Epub 2016 Aug 5.

PMID:
27501767
12.

PREDICTIVE VALUE OF SOMATIC MUTATIONS FOR THE DEVELOPMENT OF MALIGNANCY IN THYROID NODULES BY CYTOPATHOLOGY.

Halászlaki C, Tóbiás B, Balla B, Kósa JP, Horányi J, Bölöny E, Nagy Z, Speer G, Járay B, Székely E, Istók R, Székely T, Putz Z, Dank M, Lakatos P, Takács I.

Endocr Pract. 2016 Sep;22(9):1081-7. doi: 10.4158/EP151057.OR. Epub 2016 May 23.

PMID:
27214302
13.
14.

Expression of cell cycle markers is predictive of the response to primary systemic therapy of locally advanced breast cancer.

Tőkés T, Tőkés AM, Szentmártoni G, Kiszner G, Madaras L, Kulka J, Krenács T, Dank M.

Virchows Arch. 2016 Jun;468(6):675-86. doi: 10.1007/s00428-016-1925-x. Epub 2016 Mar 30.

PMID:
27026269
15.

Predictive and prognostic value of FDG-PET/CT imaging and different response evaluation criteria after primary systemic therapy of breast cancer.

Tőkés T, Kajáry K, Szentmártoni G, Lengyel Z, Györke T, Torgyík L, Somlai K, Tőkés AM, Kulka J, Dank M.

Breast Cancer. 2017 Jan;24(1):137-146. doi: 10.1007/s12282-016-0685-4. Epub 2016 Mar 15.

PMID:
26979062
16.

[Immunotherapy opportunities in breast cancer].

Pusztai L, Ladányi A, Székely B, Dank M.

Magy Onkol. 2016 Mar 2;60(1):34-40. Epub 2015 Dec 19. Hungarian.

17.

Association between Dictyocaulus viviparus status and milk production parameters in Dutch dairy herds.

Dank M, Holzhauer M, Veldhuis A, Frankena K.

J Dairy Sci. 2015 Nov;98(11):7741-7. doi: 10.3168/jds.2015-9408. Epub 2015 Aug 20.

PMID:
26298745
18.

Genetic Alterations in Hungarian Patients with Papillary Thyroid Cancer.

Tobiás B, Halászlaki C, Balla B, Kósa JP, Árvai K, Horváth P, Takács I, Nagy Z, Horváth E, Horányi J, Járay B, Székely E, Székely T, Győri G, Putz Z, Dank M, Valkusz Z, Vasas B, Iványi B, Lakatos P.

Pathol Oncol Res. 2016 Jan;22(1):27-33. doi: 10.1007/s12253-015-9969-9. Epub 2015 Aug 11.

PMID:
26259532
19.

Complexity of Response Evaluation During Primary Systemic Therapy of Breast Cancer: Scoring Systems and Beyond-Preliminary Results.

Tőkés T, Szentmártoni G, Torgyík L, Somlai K, Kulka J, Lengyel Z, Györke T, Dank M.

Anticancer Res. 2015 Sep;35(9):5063-72.

PMID:
26254408
20.

Response evaluation after primary systemic therapy of Her2 positive breast cancer – an observational cross-sectional study.

Tőkés T, Szentmártoni G, Torgyík L, Kajáry K, Lengyel Z, Györke T, Molnár BÁ, Tőkés AM, Kulka J, Dank M.

Croat Med J. 2015 Apr;56(2):128-38.

Supplemental Content

Loading ...
Support Center